



## Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

January 21, 2025

### Event will feature insights on LX9211, Lexicon's novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP

THE WOODLANDS, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company will host a virtual webcast: "LX9211 - Changing the Paradigm for Treatment of Neuropathic Pain." The event will be held from 9:00 a.m. to 11:00 a.m. ET on January 28, 2025.

In advance of topline data from the Phase 2b PROGRESS trial anticipated later this quarter, the event will offer an in-depth overview on LX9211 for the treatment of diabetic peripheral neuropathic pain (DPNP), featuring remarks from Lexicon leaders including:

- Mike Exton, PhD, Chief Executive Officer and Director
- Suma Gopinathan, PhD, Vice President, Clinical Development
- Craig Granowitz, MD, PhD, Senior Vice President and Chief Medical Officer

In addition to presentations by the Lexicon leadership team, the event will include an expert panel and Q&A session on DPNP featuring:

- Rodica Pop-Busui MD, PhD, Jordan Schnitzer Chair in Diabetes | Professor of Medicine and Division Head, Endocrinology, Diabetes and Clinical Nutrition Director, Harold Schnitzer Diabetes Center, Oregon Health & Science University | 2023 President for Medicine and Science, American Diabetes Association
- Steve Edelman, MD, Professor of Medicine, the Division of Endocrinology, Diabetes & Metabolism at University of California San Diego | Veterans Affairs Medical Center | Founder and Director Taking Control Of Your Diabetes (TCOYD)

Register for the event [here](#). The webcast will be available in the "Events" section of the Lexicon website at <https://investors.lexpharma.com/news-events/events> and a recording of the webcast will be available following the original on-demand date.

#### About Lexicon Pharmaceuticals

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through the Genome5000™ program, Lexicon's unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in cardiology, neuropathic pain, metabolism and other indications. For additional information, please visit [www.lexpharma.com](http://www.lexpharma.com).

#### For Investor and Media Inquiries:

Lisa DeFrancesco  
Lexicon Pharmaceuticals, Inc.  
[lexinvest@lexpharma.com](mailto:lexinvest@lexpharma.com)